产品
编 号：F432749
分子式：C11H8O2
分子量：172.18
分子式：C11H8O2
分子量：172.18
产品类型
规格
价格
是否有货
25g
询价
询价
50g
询价
询价
结构图
CAS No: 708-06-5
产品详情
生物活性：
CFL-137 is a potent KRasG12C inhibitor. CFL-137 shows an antiproliferative effect. CFL-137 shows anticancer activity. CFL-137 has the potential for the research of lung cancer.
体内研究：
CFL-137 (5 mg/kg，5 次治疗；15 mg/kg，5 次治疗；30 mg/kg，3 次治疗；i.p.) 减少皮下人肺癌 H1792 (KRasG12C 突变体) 和 LCLC-103H (KRasWT) 小鼠肿瘤模型的生长。Animal Model:NOD/SCID female mice (KRasWT (LCLC-103H) or KRasG12C (H1792) tumors)
Dosage:5 mg/kg, 5 treatments; 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments
Administration:I.p.
Result:Reduced tumor growth compared to the control group in KRasG12C mutated model for 32.5%.
体外研究：
CFL-137 (72 h) 显示出抗增殖作用，对 H1792, SW1573, MiaPaca2, H358, A549, SW480, PANC-1, LCLC-103H, BxPC3, HCA-7, MRC-5, HUVEC-TERT, CCD-986Sk 细胞的 IC50 值分别为 11.4, 24.2, 24.5, 12.3, 43.3, 44.5, 27.63, 32.4, 46.9, 26.2, 25.0, 10.8, 66.2 μM。
CFL-137 is a potent KRasG12C inhibitor. CFL-137 shows an antiproliferative effect. CFL-137 shows anticancer activity. CFL-137 has the potential for the research of lung cancer.
体内研究：
CFL-137 (5 mg/kg，5 次治疗；15 mg/kg，5 次治疗；30 mg/kg，3 次治疗；i.p.) 减少皮下人肺癌 H1792 (KRasG12C 突变体) 和 LCLC-103H (KRasWT) 小鼠肿瘤模型的生长。Animal Model:NOD/SCID female mice (KRasWT (LCLC-103H) or KRasG12C (H1792) tumors)
Dosage:5 mg/kg, 5 treatments; 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments
Administration:I.p.
Result:Reduced tumor growth compared to the control group in KRasG12C mutated model for 32.5%.
体外研究：
CFL-137 (72 h) 显示出抗增殖作用，对 H1792, SW1573, MiaPaca2, H358, A549, SW480, PANC-1, LCLC-103H, BxPC3, HCA-7, MRC-5, HUVEC-TERT, CCD-986Sk 细胞的 IC50 值分别为 11.4, 24.2, 24.5, 12.3, 43.3, 44.5, 27.63, 32.4, 46.9, 26.2, 25.0, 10.8, 66.2 μM。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备